{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:20:10Z","timestamp":1781911210398,"version":"3.54.5"},"reference-count":22,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2012,12,28]],"date-time":"2012-12-28T00:00:00Z","timestamp":1356652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>This retrospective study was performed to verify the efficacy and safety of Onabotulinumtoxin A (BTX-A) in treating children with neurogenic bladder (NB) secondary to myelomeningocele (MMC) with detrusor overactivity\/low compliance. From January 2002 to June 2011, 47 patients out of 68 with neuropathic bladder were selected (22 females, 25 males, age range 5\u201317 years; mean age 10.7 years at first injection). They presented overactive\/poor compliant neurogenic bladders on clean intermittent catheterization, and were resistant or non compliant to pharmacological therapy. Ten patients presented second to fourth grade concomitant monolateral\/bilateral vesicoureteral reflux (VUR). All patients were incontinent despite catheterization. In the majority of patients Botulinum-A toxin was administered under general\/local anesthesia by the injection of 200 IU of toxin, without exceeding the dosage of 12IU\/kg body weight, diluted in 20 cc of saline solution in 20 sites, except in the periureteral areas. Follow-up included clinical and ultrasound examination, urodynamics performed at 6, 12 and 24 weeks, and annually thereafter. Seven patients remained stable, 21 patients required a second injection after 6\u20139 months and 19 a third injection. VUR was corrected, when necessary, in the same session after the BT-A injection, by 1\u20133 cc of subureteral Deflux\u00ae. Urodynamic parameters considered were leak point pressure (LPP), leak point volume (LPV) and specific volume at 20 cm H2O pressure. The results were analyzed using the Wilcoxon test. All patients experienced a significant 66.45% average increase of LPV (Wilcoxon paired rank test = 7169 \u00d7 10 \u221210) and a significant 118.57% average increase of SC 20 (Wilcoxon paired rank test = 2.466 \u00d7 10 \u221212). The difference between preoperative and postoperative LPP resulted not significant (Wilcoxon paired rank test = 0.8858) No patient presented severe systemic complications; 38\/47 patients presented slight hematuria for 2\u20133 days. Two patients had postoperative urinary tract infection. All patients were hospitalized for 24 h with catheterization. Thirty-eight out of 47 patients achieved dryness between CIC; nine patients improved their incontinence but still need pads. Ten patients have resumed anticholinergic agents. Our results suggest that the use of BTX-A is safe and effective in patients with MMC with a positive effect on their dryness and quality of life.<\/jats:p>","DOI":"10.3390\/toxins5010016","type":"journal-article","created":{"date-parts":[[2012,12,28]],"date-time":"2012-12-28T10:59:11Z","timestamp":1356692351000},"page":"16-24","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Onabotulinumtoxin A for Treating Overactive\/Poor Compliant Bladders in Children and Adolescents with Neurogenic Bladder Secondary to Myelomeningocele"],"prefix":"10.3390","volume":"5","author":[{"given":"Antonio","family":"Marte","sequence":"first","affiliation":[{"name":"Pediatric Surgery 2nd University of Naples, Via Pansini 5, Naples 80131, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2012,12,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00042307-200211000-00004","article-title":"Neurogenic bladder dysfunction in patients with myelomeningocele","volume":"12","author":"Madersbacher","year":"2002","journal-title":"Curr. Opin. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0302-2838(03)00136-2","article-title":"Botulinum-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder","volume":"44","author":"Michael","year":"2003","journal-title":"Eur. Urol."},{"key":"ref_3","first-page":"35","article-title":"La Tossina A-Botulinica in bambini con vescica neurogena iperattiva secondaria a mielomeningocele refrattaria agli urofarmaci: Una alternativa all enterocistoplastica","volume":"57","author":"Marte","year":"2005","journal-title":"Minerva Pediatr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.eururo.2003.12.004","article-title":"European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity","volume":"45","author":"Reitz","year":"2004","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Sussman, D., Patel, V., del Popolo, G., Lam, W., Globe, D., and Pommerville, P. (2012). Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol. Urodyn.","DOI":"10.1002\/nau.22293"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jpurol.2007.10.008","article-title":"Total endoscopic management (TEM approach) of children with non-compliant neuropathic bladder: A preliminary report","volume":"4","author":"Neel","year":"2008","journal-title":"J. Pediatr. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0022-5347(17)54449-3","article-title":"Prognostic value urodynamic testing in myelodysplastic patients","volume":"126","author":"Woodside","year":"1981","journal-title":"J. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0022-5347(17)36148-7","article-title":"What volume can a child normally store in the bladder at a safe pressure?","volume":"149","author":"Houle","year":"1993","journal-title":"J. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1055\/s-0029-1246193","article-title":"Effectiveness of botulinum-A toxin for the treatment of refractory overactive bladder in children","volume":"20","author":"Marte","year":"2010","journal-title":"Eur. J. Pediatr. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/365160a0","article-title":"Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25","volume":"365","author":"Blasi","year":"1993","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.1526-4610.43.7s.4.x","article-title":"Synaptic transmission: Inhibition of neurotransmitter release by botulinum toxins","volume":"43","author":"Dolly","year":"2003","journal-title":"Headache"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0168-6054(03)00113-2","article-title":"Efficacy of botulinum toxin A for the treatment of detrusor hyperreflexia","volume":"46","author":"Denys","year":"2003","journal-title":"Ann. Readapt. Med. Phys."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0302-2838(03)00250-1","article-title":"Botulinum toxin as a new therapy option for voiding disorders: Current state of the art","volume":"44","author":"Leippold","year":"2003","journal-title":"Eur. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0022-5347(05)67283-7","article-title":"Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results","volume":"164","author":"Schurch","year":"2000","journal-title":"J. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.eururo.2008.07.030","article-title":"A minimally invasive approach in the treatment of vesicoureteral reflux in neurogenic bladder in children","volume":"55","author":"Mosiello","year":"2009","journal-title":"Eur. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00345-008-0362-0","article-title":"A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging","volume":"27","author":"Mehnert","year":"2009","journal-title":"World J. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0022-5347(05)66438-5","article-title":"Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction","volume":"165","author":"Phelan","year":"2001","journal-title":"J. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1159\/000331726","article-title":"Results of a BoNT\/An antibody study in children and adolescents after onabotulinumtoxin A (Botox\u00ae) detrusor injection","volume":"87","author":"Herholz","year":"2011","journal-title":"Urol. Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jpurol.2009.01.005","article-title":"Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity\/neurogenic overactive bladder: A systematic literature review","volume":"5","author":"Mouracade","year":"2009","journal-title":"J. Pediatr. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.eururo.2004.11.009","article-title":"Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence","volume":"47","author":"Grosse","year":"2005","journal-title":"Eur. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00345-009-0466-1","article-title":"Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany","volume":"28","author":"Wefer","year":"2010","journal-title":"World J. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Mohee, A., Khan, A., Harris, N., and Eardley, I. (2012). Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int.","DOI":"10.1111\/j.1464-410X.2012.11282.x"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/5\/1\/16\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:54:32Z","timestamp":1760219672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/5\/1\/16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,28]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1]]}},"alternative-id":["toxins5010016"],"URL":"https:\/\/doi.org\/10.3390\/toxins5010016","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,28]]}}}